Inactivation of DNA repair-prospects for boosting cancer immune surveillance

Area of Science:

• Oncology
• Cancer Genomics
• Immunology

Background:

• Cancer cells develop drug resistance via genomic mutation and evolution under selective pressures.
• Alterations in DNA repair genes accelerate the generation of new mutations, contributing to resistance.
• This genomic plasticity is a key factor in cancer progression and treatment failure.

Purpose of the Study:

• To explore the dual role of cancer cell genomic mutations in drug resistance and immune response.
• To understand how DNA repair pathway alterations impact cancer evolution and antigenicity.
• To investigate the interplay between acquired mutations, therapeutic outcomes, and anti-tumor immunity.

Main Methods:

• Analysis of cancer cell genomics and mutation profiles.
• Assessment of DNA repair pathway gene status.
• Evaluation of tumor microenvironment and immune cell infiltration.
• Correlation of mutation patterns with drug resistance and patient survival data.

Main Results:

• Genomic mutations are essential for cancer cells to evolve drug resistance.
• Accelerated mutation rates, often due to DNA repair defects, fuel this evolution.
• Paradoxically, newly emerged cancer variants can act as neoantigens, stimulating immune surveillance.
• This immune response can potentially restrict tumor growth despite acquired resistance.

Conclusions:

• Cancer cell evolution underpins drug resistance, driven by genomic instability.
• While promoting resistance, mutations can also generate neoantigens that enhance anti-cancer immunity.
• Targeting DNA repair pathways and leveraging neoantigen presentation are potential therapeutic strategies.